Physician profile
Marco Chavez
NPI 1033566435
$9,345.24
in general payments reported to CMS, 2019-2025
46 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $481 · 2021: $1,643 · 2022: $1,958 · 2023: $2,294 · 2024: $1,751 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,138.96 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,039.19 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $825.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $741.38 | 2021-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $593.67 | 2020-2025 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $565.41 | 2021-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.42 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $487.88 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $423.80 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $378.81 | 2020-2025 | Belsomra, Steglatro, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $249.92 | 2021-2024 | Ajovy, Austedo Xr, Austedo |
| Astellas Pharma US INC | $248.35 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $176.01 | 2020-2024 | Rexulti |
| Amarin Pharma, INC. | $172.66 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.18 | 2022-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.